Published: July 26, 2023
Last updated: August 17, 2023
GBI’s Chief Scientific Officer, Muctarr Sesay, has participated in Pharma Almanac’s 2023 roundtable discussion.
The topic of discussion is “In what areas of pharma/biopharma are you most excited to see increased adoption of artificial intelligence (AI) and machine learning?”
Dr. Sesay mentions, “AI and machine learning tools becoming more accessible in the coming years will facilitate faster and cheaper drug discoveries, manufacturing and commercialization, thereby becoming part of the natural process in the biopharma industry- not only for the large multi-national companies but also mid-sized to small pharmaceutical companies and CDMOs”
Click here to read the full article to learn more!
